Ibrutinib Showing Positive Results in the Frontline Setting - 101868

Spotlight
Video

Ibrutinib Showing Positive Results in the Frontline Setting

Loading........
Description: At the American Society of Hematology (ASH) meeting in Orlando, CLL expert Dr. Jan Burger discussed the result from the RESONATE-2 trial, which studied the use of ibrutinib (Imbruvica) vs. chlorambucil in the frontline setting in patients over 65. Dr. Burger reviews the medication’s benefits in overall survival, progression free survival, and in response rates. Learn why Dr. Burger feels it is “compelling to use ibrutinib more in the frontline setting” for elderly patients.

Get email alerts | http://www.patientpower.inf...

Subscribe on YouTube | http://www.youtube.com/pati...
Like on Facebook | http://www.fb.com/patientpo...
Follow on Twitter | http://www.twitter.com/pati...
Follow on Google+ | http://www.google.com/+pati...
Shared By : P2Professional
Posted on : 12/16/15
Added : 3 years ago